Abiomed's Heart Pump Can Improve Outcomes in Some Patients

The use of Abiomed's (NASDAQ: ABMD) Impella heart pumps reduced the rate of death, stroke, myocardial infarction, and repeat procedures in high-risk percutaneous coronary intervention (PCI) patients, according to a new study.

The interim data from the healthcare company's single-arm PROTECT III study reflects patient outcomes for 1,143 patients who underwent elective non-emergent PCI with an Impella pump between March 2017 and September 2019.

A woman in a lab coat speaking through a megaphone.


Previously, Abiomed's PROTECT II study data showed use of an Impella pump improved patient outcomes by 29% versus an intra-aortic balloon pump at 90 days. An analysis of the PROTECT III data revealed that patients who would have qualified for enrollment in PROTECT II had a lower rate of adverse outcomes compared to PROTECT II patients -- 15% compared to 21.9% despite those patients being generally older and sicker with more comorbidities than PROTECT II patients.

The new data will be used alongside previous results to inform the design of Abiomed's future two-arm PROTECT IV randomized control trial (RCT), which will compare PCI with Impella against PCI without any planned hemodynamic support.

The additional data from Abiomed's study may help expand use of Impella pumps to more PCI procedures, resulting in sales growth. In it's most recently reported fiscal quarter, Abiomed reported revenue of $165 million, down 21% year over year because of delayed procedures caused by COVID-19 restrictions.

10 stocks we like better than Abiomed
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abiomed wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 24, 2020

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Abiomed. The Motley Fool has a disclosure policy.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More